Literature DB >> 26629134

Genetic polymorphisms of Trim5a are associated with disease progression in acutely and chronically HIV-infected patients.

Xin Sun1, Wei Li1, Wenzhen Liu2, Rui Wang1, Qunhui Li1, Hao Wu1.   

Abstract

BACKGROUND: The tripartite interaction motif 5a (Trim5a) plays critical roles in restricting various kinds of retroviruses in different species. It has been shown that Trim5a could inhibit HIV-1 inhibition in vitro.
METHODS: In this study, 16 SNPs of Trim5a gene were screened in 236 acutely HIV-infected patients (169 common type (CT) patients and 67 patients with rapid disease progression). In addition, they were screened in 162 chronically HIV-infected patients (147 common type patients and 15 long-term non-progressors (LTNP)). The potential effects of polymorphisms at Trim5a genes on HIV-infection disease progression were analyzed.
RESULTS: Among all tested SNP sites, 3 SNPs (rs3824949, rs2291841 and rs11038628) were identified to be associated with rapid disease progression in acutely HIV-infected patients. Carriage of rs3824949 allele G, rs2291841 allele C or rs11038628 allele T associated with rapid disease progression. In chronically HIV-infected patients, Patients carrying rs3802981 allele C or rs3802980 allele A had increased opportunity to be LTNP. We also found that greater age was associated with disease deterioration.
CONCLUSIONS: Different genetic polymorphisms of Trim5a may have an impact on the clinical course of both acute and chronic stages of HIV-infection.

Entities:  

Keywords:  HIV-1; Trim5a; disease progression; genetic polymorphisms

Year:  2015        PMID: 26629134      PMCID: PMC4659023     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.

Authors:  Hassan Javanbakht; Ping An; Bert Gold; Desiree C Petersen; Colm O'Huigin; George W Nelson; Stephen J O'Brien; Gregory D Kirk; Roger Detels; Susan Buchbinder; Sharyne Donfield; Sergey Shulenin; Byeongwoon Song; Michel J Perron; Matthew Stremlau; Joseph Sodroski; Michael Dean; Cheryl Winkler
Journal:  Virology       Date:  2006-08-02       Impact factor: 3.616

2.  TRIM5 allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies.

Authors:  N G de Groot; C M C Heijmans; G Koopman; E J Verschoor; W M Bogers; R E Bontrop
Journal:  Tissue Antigens       Date:  2011-10

3.  [The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up].

Authors:  Paz Sobrino-Vegas; Félix Gutiérrez; Juan Berenguer; Pablo Labarga; Federico García; Belén Alejos-Ferreras; M Angeles Muñoz; Santiago Moreno; Julia del Amo
Journal:  Enferm Infecc Microbiol Clin       Date:  2011-08-05       Impact factor: 1.731

4.  A naturally occurring single amino acid substitution in human TRIM5α linker region affects its anti-HIV type 1 activity and susceptibility to HIV type 1 infection.

Authors:  Emi E Nakayama; Toshiaki Nakajima; Gurvinder Kaur; Jun-ich Mimaya; Hiroshi Terunuma; Narinder Mehra; Akinori Kimura; Tatsuo Shioda
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-26       Impact factor: 2.205

5.  Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study.

Authors:  Jason F Okulicz; Vincent C Marconi; Michael L Landrum; Scott Wegner; Amy Weintrob; Anuradha Ganesan; Braden Hale; Nancy Crum-Cianflone; Judith Delmar; Vincent Barthel; Gerald Quinnan; Brian K Agan; Matthew J Dolan
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

Review 6.  Mechanisms involved in non-progressive HIV disease.

Authors:  Meriet Mikhail; Bin Wang; Nitin K Saksena
Journal:  AIDS Rev       Date:  2003 Oct-Dec       Impact factor: 2.500

7.  Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.

Authors:  Emily C Speelmon; Devon Livingston-Rosanoff; Shuying Sue Li; Quyen Vu; John Bui; Daniel E Geraghty; Lue Ping Zhao; M Juliana McElrath
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

8.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

10.  The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection.

Authors:  Daniëlle van Manen; Maarten A N Rits; Corrine Beugeling; Karel van Dort; Hanneke Schuitemaker; Neeltje A Kootstra
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

View more
  2 in total

1.  Variations in Trim5α and Cyclophilin A genes among HIV-1 elite controllers and non controllers in Uganda: a laboratory-based cross-sectional study.

Authors:  Sharon Bright Amanya; Brian Nyiro; Francis Waswa; Bonniface Obura; Rebecca Nakaziba; Eva Nabulime; Ashaba Fred Katabazi; Rose Nabatanzi; Alice Bayiyana; Gerald Mboowa; Alex Kayongo; Misaki Wayengera; Obondo J Sande
Journal:  Retrovirology       Date:  2020-07-06       Impact factor: 4.602

2.  Defects in assembly explain reduced antiviral activity of the G249D polymorphism in human TRIM5α.

Authors:  Sevnur Kömürlü; Margret Bradley; Nikolai Smolin; Sabrina Imam; Raymond F Pauszek; Seth L Robia; David Millar; Emi E Nakayama; Tatsuo Shioda; Edward M Campbell
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.